NasdaqCM:OTLKBiotechs
Is Outlook Therapeutics (OTLK) Fully Valued As FDA Approval Reshapes Its Prospects?
Outlook Therapeutics (OTLK) has just secured U.S. Food and Drug Administration approval for LYTENAVA, the first ophthalmic bevacizumab cleared for neovascular age-related macular degeneration in the United States. This development reshapes the company’s investment story.
See our latest analysis for Outlook Therapeutics.
At a share price of US$1.04, Outlook Therapeutics has seen a 90 day share price return of almost 3x, even after the 30 day share price return fell 34.59% and the 1 year total...